Clinical trials: COPD Exacerbation
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)
The aim of the study is to compare the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297115
- Testing
- Roflumilast
- Where
- 287 sites in United States, Canada and 6 more
- Volunteers
- 1,568 people
- Sponsor
- AstraZeneca
COPD Exacerbation
Early Assisted Discharge for COPD Exacerbations With Telemonitoring.
To determine if an early assisted discharge program for acute exacerbations of COPD (AECOPD), with telemonitoring and telephone control, is equally effective and more efficient in terms of use of health care resources, that a…
- Trial name
- NCT01951261
- Testing
- Telemonitoring and telephone control
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Dr. López Viña
COPD, Chronic Bronchitis
Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation
The purpose of this study is to show that one form of mechanical airway clearance techniques, High Frequency Chest Wall Oscillation (HFCWO)using a pneumatic vest, will diminish exacerbations of COPD which will improve respiratory…
- Conditions
- COPD, Chronic Bronchitis, Emphysema
- Trial name
- NCT00181207
- Testing
- pneumatic vest
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Johns Hopkins University
Chronic Obstructive Pulmonary Disease (COPD)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)
The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00297102
- Testing
- Roflumilast
- Where
- 179 sites in United States, Australia and 9 more
- Volunteers
- 1,523 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.
- Trial name
- SPARK (NCT01120691)
- Testing
- QVA149, NVA237, tiotropium
- Where
- 342 sites in United States, Argentina and 26 more
- Volunteers
- 2,224 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.
- Trial name
- NCT00419744
- Testing
- Budesonide/formoterol (SYMBICORT) pMDI, Formoterol Turbuhaler
- Where
- 140 sites in United States, Argentina and 7 more
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Digihaler in Chronic Obstructive Pulmonary Disease (COPD)
This is a multi-center 3-month study to determine the variation in ProAir Digihaler metrics [peak inspiratory flow (PIF), inhalation volume, number of inhalation events] amongst COPD patients in the ambulatory setting.
- Trial name
- NCT05241288
- Testing
- Albuterol eMDPI DS
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill
COPD, Eosinophilia
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
This is a single-centre, double-blinded, randomised, placebo controlled trial comparing mepolizumab 100mg versus placebo in patients with eosinophilic COPD, started following their index admission to hospital.
- Trial name
- COPD-HELP (NCT04075331)
- Testing
- Mepolizumab
- Where
- United Kingdom
- Volunteers
- 238 people
- Sponsor
- University of Leicester
Pulmonary Disease, Chronic Obstructive
Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals.
- Trial name
- LEUKO (NCT00493974)
- Testing
- Zileuton
- Where
- 18 sites in United States
- Volunteers
- 119 people
- Sponsor
- University of Minnesota
Respiratory Disorders
A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.
The purpose of this study is to test if the vaccine is working well in COPD patients aged 40 to 80 years old to reduce episodes of worsening symptoms ("exacerbations") and to gather further information on safety and immune…
- Trial name
- NCT03281876
- Testing
- NTHi Mcat investigational vaccine (GSK3277511A)
- Where
- 67 sites in United States, Belgium and 6 more
- Volunteers
- 606 people
- Sponsor
- GlaxoSmithKline
COPD Exacerbation
COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers
The purpose of this study is to compare drug delivery and lung function after treatment with formoterol from a nebulizer versus a dry powder inhaler (DPI) in patients recovering from severe exacerbations of COPD.
- Trial name
- NCT02291016
- Testing
- Formoterol
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Tennessee Graduate School of Medicine
COPD
Efficacy and Safety of AQX-1125 in Unstable COPD
The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease…
- Trial name
- FLAGSHIP (NCT01954628)
- Testing
- AQX-1125
- Where
- 8 sites in United States, Australia and 6 more
- Volunteers
- 400 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation
Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Some patients with chronic obstructive pulmonary diseases (COPD) have large number of specific white blood cells called eosinophils in their airways.
- Conditions
- Chronic Obstructive Pulmonary Diseases, Chronic Airways Limitation, Bronchitis
- Trial name
- NCT01463644
- Testing
- Mepolizumab
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- McMaster University
Chronic Obstructive Pulmonary Disease
Integrating Care After Exacerbation of COPD
This clinical trial is designed to determine whether an intervention that provides information to primary care providers about gaps in care for their patients recently discharged from hospital for COPD can reduce hospital…
- Trial name
- InCasE (NCT02021955)
- Testing
- guideline treatment recommendations
- Where
- 2 sites in United States
- Volunteers
- 717 people
- Sponsor
- VA Office of Research and Development
Pulmonary Disease, Chronic Obstructive
An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the efficacy of GSK2269557 administered in addition to standard of care in adult subjects diagnosed with an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT02294734
- Testing
- GSK2269557
- Where
- 17 sites in Belgium, Denmark and 3 more
- Volunteers
- 126 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation
This study will assess preliminary parameters of safety and efficacy of a single dose of BCT197 in patients with a Chronic Obstructive Pulmonary Disease (COPD) exacerbation.
- Trial name
- NCT01332097
- Testing
- BCT197, Prednisone
- Where
- 6 sites in Bulgaria, Romania and 1 more
- Volunteers
- 183 people
- Sponsor
- Mereo BioPharma
COPD Exacerbation
Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD
The primary objective of the study is to determine the percentage of patients with "therapeutic success" at the end of the cycle of antibiotic therapy (10 days), in the two treatment groups (levofloxacin and prulifloxacin).
- Trial name
- FLOR (NCT01710488)
- Testing
- Levofloxacin 1 tablet 500 mg once a day, Prulifloxacin 1 tablet 600 mg once a day
- Where
- 25 sites in Italy
- Volunteers
- 258 people
- Sponsor
- Fadoi Foundation, Italy
Chronic Obstructive Pulmonary Disease, Acute Exacerbation of COPD
Effect of Blood Flow Restriction Resistance Exercises in COPDAE In-patient Rehabilitation
This is a randomised controlled trial of the blood flow restriction resistance exercise (BFR-RE) for early rehabilitation of chronic obstructive pulmonary disease acute exacerbation (COPDAE) in the Haven of Hope Hospital.
- Trial name
- NCT04448236
- Testing
- Blood flow restriction resistance exercise
- Where
- Hong Kong
- Volunteers
- 53 people
- Sponsor
- Hospital Authority, Hong Kong
Chronic Obstructive Pulmonary Disease With Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation
Bubble PEP Training Among Patient With Chronic Obstructive Pulmonary Disease in Pulmonary Function Effects
The morbidity rate of Chronic Obstructive Pulmonary Disease (COPD) is increasing year by year. It is predicted to be the third leading cause of death worldwide in 2030.
- Conditions
- Chronic Obstructive Pulmonary Disease With Exacerbation, Chronic Obstructive Pulmonary Disease Exacerbation, Chronic Pulmonary Disease
- Trial name
- NCT04828837
- Testing
- bubble PEP
- Where
- Taiwan
- Volunteers
- 57 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Chronic Obstructive Pulmonary Disease
Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD
This study is evaluating the use of a respiratory device, the Acapella Vibratory Positive Expiratory Pressure (PEP) Therapy device, in patients admitted to the hospital with a chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03094806
- Testing
- Acapella Vibratory PEP Therapy Device plus usual care
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital